Shots:
- Abbott has received the US FDA clearance & European CE Mark for its Amplatzer Piccolo Delivery System, used with Amplatzer Piccolo Occluder, to treat premature babies (≥2lbs) with patent ductus arteriosus (PDA; hole in the heart)
- Approved in the US & EU in 2019, Amplatzer Piccolo Occluder is a minimally invasive transcatheter device, smaller than a pea, to close PDA in premature infants, which is now equipped with a delivery system
- Amplatzer Piccolo is delivered via a small leg incision & guided to the heart using a single, shorter & softer catheter, simplifying implantation & enabling more precise placement in premature infants
Ref: Abbott | Image: Abbott | Press Release
Related News: Abbott Expands Leadership in Cancer Diagnostics with ~$23B Acquisition of Exact Sciences
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
